Zirapan-DSR Capsule contains a combination of Domperidone 30mg and Pantoprazole 40mg, formulated to provide effective management of gastrointestinal disorders. Domperidone is a dopamine antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combination of these two agents in Zirapan-DSR Capsule offers a synergistic effect, addressing both motility and acid secretion abnormalities, making it suitable for patients with symptomatic GERD, functional dyspepsia, and other acid-peptic disorders accompanied by delayed gastric emptying. Zirapan-DSR should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Common side effects may include headache, dry mouth, and abdominal discomfort. Caution is advised in patients with cardiac conditions or those taking medications that may interact with domperidone or pantoprazole. This combination therapy enhances patient compliance by reducing pill burden while effectively managing complex gastrointestinal symptoms.